ESTUTC-5 New YorkLog in Sign up

GLUE
Monte Rosa Therapeutics, Inc. Common Stock
stockNASDAQ

At CloseNov 13, 2026 3:59:57 PM EST

9.37USD+0.644%(+0.06)1,119,299

Pre-marketNov 13, 2026 9:27:30 AM EST

9.38USD+0.752%(+0.07)

After-hoursNov 13, 2026 4:00:30 PM EST

9.37USD0.000%(0.00)

GLUE News

Day breaks

07:50 AM ESTMonte Rosa Therapeutics (GLUE) Reports Promising Preclinical Data for MRT-8102 Targeting Gout ... ·

GuruFocus

07:00 AM ESTMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout ·

GlobeNewswire Inc.

10:14 AM ESTGLUE Maintained by Wells Fargo -- Price Target Lowered to $25.00 ·

GuruFocus

10:08 AM ESTMonte Rosa Therapeutics earnings beat by $0.19, revenue topped estimates ·

Investing.com

07:28 AM ESTMonte Rosa Therapeutics reports Q3 results ·

Seeking Alpha

07:00 AM ESTMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates ·

GlobeNewswire Inc.

04:01 PM ESTMonte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

07:00 AM EDTMonte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) ·

GlobeNewswire Inc.

04:01 PM EDTMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

04:00 PM EDTMonte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript ·

Seeking Alpha

08:39 AM EDTMonte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 data ·

Seeking Alpha

07:00 AM EDTMonte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk ·

GlobeNewswire Inc.

06:50 AM EDTAt a glance: stocks gapping up premarket ·

Seeking Alpha

04:01 PM EDTMonte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk ·

GlobeNewswire Inc.